Development of a Human Antibody Against CEA Protein
Author Information
Author(s): Pavoni Emiliano, Flego Michela, Dupuis Maria Luisa, Barca Stefano, Petronzelli Fiorella, Anastasi Anna Maria, D'Alessio Valeria, Pelliccia Angela, Vaccaro Paola, Monteriù Giorgia, Ascione Alessandro, De Santis Rita, Felici Franco, Cianfriglia Maurizio, Minenkova Olga
Primary Institution: Kenton Labs, c/o Sigma-Tau, Italy
Hypothesis
Can a human scFv antibody be developed to effectively target the carcinoembryonic antigen (CEA) protein?
Conclusion
The new scFv E8 antibody shows high affinity for the CEA epitope and has potential as an anticancer therapeutic agent.
Supporting Evidence
- The scFv E8 antibody binds selectively to the CEA epitope expressed by metastatic melanoma and colon and lung carcinomas.
- E8 scFv shows improved affinity compared to the original MA39 antibody.
- The antibody is human-derived, reducing the risk of immunogenicity.
- Flow cytometry confirmed the specificity of E8 for CEA-expressing cells.
- Immunohistochemistry demonstrated E8's ability to stain tumor tissues without affecting normal tissues.
Takeaway
Scientists created a new human antibody that can find and attach to a specific protein found in certain cancers, which could help in treating those cancers.
Methodology
The study involved isolating a human scFv antibody from a synthetic library, followed by in vitro mutagenesis to improve its affinity for the CEA protein.
Limitations
The study does not address the long-term effects of using the antibody in clinical settings.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website